Theravance Biopharma, Inc. Payments to Acquire Productive Assets
Theravance Biopharma, Inc. (TBPH) reported Payments to Acquire Productive Assets of $42.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2026-08-11
- Theravance Biopharma, Inc. payments to acquire productive assets for the quarter ending 2025-12-31 was $8.00K, a 95.79% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire productive assets for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire productive assets for the quarter ending 2024-12-31 was $190.00K, a 71.94% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire productive assets for the quarter ending 2024-09-30 was $15.00K, a 28.57% decline year-over-year.
- Theravance Biopharma, Inc. payments to acquire productive assets for fiscal 2025 was $42.00K, a 87.35% decline from fiscal 2024.
- Theravance Biopharma, Inc. payments to acquire productive assets for fiscal 2024 was $332.00K, a 86.66% decline from fiscal 2023.
- Theravance Biopharma, Inc. payments to acquire productive assets for fiscal 2023 was $2.49M, a 334.97% increase from fiscal 2022.
- Theravance Biopharma, Inc. payments to acquire productive assets for fiscal 2022 was $572.00K, a 83.21% decline from fiscal 2021.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month | Payments to Acquire Productive Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $8.00K derived: sum of 2 quarters · filed 2026-03-23 | $42.00K 10-K · filed 2026-03-23 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $34.00K 10-Q · filed 2025-11-12 | ||
| 2025-06-30 | $34.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $190.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $205.00K derived: sum of 2 quarters · filed 2026-03-23 | $241.00K derived: sum of 3 quarters · filed 2026-03-23 | $332.00K 10-K · filed 2026-03-23 |
| 2024-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $51.00K derived: sum of 2 quarters · filed 2025-11-12 | $142.00K 10-Q · filed 2025-11-12 | $819.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $36.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $127.00K 10-Q · filed 2025-08-13 | $804.00K derived: sum of 3 quarters · filed 2025-08-13 | $825.00K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $91.00K 10-Q · filed 2025-05-12 | $768.00K derived: sum of 2 quarters · filed 2025-05-12 | $789.00K derived: sum of 3 quarters · filed 2025-05-12 | $1.64M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $677.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $698.00K derived: sum of 2 quarters · filed 2025-03-07 | $1.55M derived: sum of 3 quarters · filed 2025-03-07 | $2.49M 10-K · filed 2025-03-07 |
| 2023-09-30 | $21.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $873.00K derived: sum of 2 quarters · filed 2024-11-14 | $1.81M 10-Q · filed 2024-11-14 | $2.08M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $852.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.79M 10-Q · filed 2024-08-08 | $2.06M derived: sum of 3 quarters · filed 2024-08-08 | $2.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $938.00K 10-Q · filed 2024-05-15 | $1.20M derived: sum of 2 quarters · filed 2024-05-15 | $1.15M derived: sum of 3 quarters · filed 2024-05-15 | $1.26M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $266.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $209.00K derived: sum of 2 quarters · filed 2024-03-01 | $322.00K derived: sum of 3 quarters · filed 2024-03-01 | $572.00K 10-K · filed 2024-03-01 |
| 2022-09-30 | -$57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $56.00K derived: sum of 2 quarters · filed 2023-11-09 | $306.00K 10-Q · filed 2023-11-09 | $750.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $363.00K 10-Q · filed 2023-08-09 | $807.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.85M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $250.00K 10-Q · filed 2023-05-10 | $694.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.73M derived: sum of 3 quarters · filed 2023-05-10 | $1.89M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $444.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $1.48M derived: sum of 2 quarters · filed 2023-03-01 | $1.64M derived: sum of 3 quarters · filed 2023-03-01 | $3.41M 10-K · filed 2023-03-01 |
| 2021-09-30 | $1.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $1.20M derived: sum of 2 quarters · filed 2022-11-09 | $2.96M 10-Q · filed 2022-11-09 | $4.21M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $1.92M 10-Q · filed 2022-08-08 | $3.17M derived: sum of 3 quarters · filed 2023-03-01 | $5.22M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $1.77M 10-Q · filed 2022-05-06 | $3.01M derived: sum of 2 quarters · filed 2023-03-01 | $5.06M derived: sum of 3 quarters · filed 2023-03-01 | $7.43M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $3.29M derived: sum of 2 quarters · filed 2023-03-01 | $5.66M derived: sum of 3 quarters · filed 2023-03-01 | $6.62M 10-K · filed 2023-03-01 |
| 2020-09-30 | $2.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $4.42M derived: sum of 2 quarters · filed 2021-11-08 | $5.37M 10-Q · filed 2021-11-08 | $6.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $3.32M 10-Q · filed 2021-08-05 | $4.63M derived: sum of 3 quarters · filed 2022-02-28 | $4.70M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $954.00K 10-Q · filed 2021-05-06 | $2.26M derived: sum of 2 quarters · filed 2022-02-28 | $2.33M derived: sum of 3 quarters · filed 2022-02-28 | $2.91M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.38M derived: sum of 2 quarters · filed 2022-02-28 | $1.96M derived: sum of 3 quarters · filed 2022-02-28 | $3.18M 10-K · filed 2022-02-28 |
| 2019-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $653.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.87M 10-Q · filed 2020-11-09 | $3.37M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $576.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.80M 10-Q · filed 2020-08-10 | $3.30M derived: sum of 3 quarters · filed 2021-02-26 | $5.17M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $1.22M 10-Q · filed 2020-05-08 | $2.72M derived: sum of 2 quarters · filed 2021-02-26 | $4.59M derived: sum of 3 quarters · filed 2021-02-26 | $5.69M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $3.38M derived: sum of 2 quarters · filed 2021-02-26 | $4.47M derived: sum of 3 quarters · filed 2021-02-26 | $7.24M 10-K · filed 2021-02-26 |
| 2018-09-30 | $1.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $2.97M derived: sum of 2 quarters · filed 2019-11-08 | $5.74M 10-Q · filed 2019-11-08 | $6.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $1.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $3.87M 10-Q · filed 2019-08-05 | $4.12M derived: sum of 3 quarters · filed 2020-02-27 | $4.95M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $2.77M 10-Q · filed 2019-05-10 | $3.03M derived: sum of 2 quarters · filed 2020-02-27 | $3.85M derived: sum of 3 quarters · filed 2020-02-27 | $4.59M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $255.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $1.08M derived: sum of 2 quarters · filed 2020-02-27 | $1.82M derived: sum of 3 quarters · filed 2020-02-27 | $2.41M 10-K · filed 2020-02-27 |
| 2017-09-30 | $826.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.56M derived: sum of 2 quarters · filed 2018-11-08 | $2.15M 10-Q · filed 2018-11-08 | $2.55M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $738.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $1.32M 10-Q · filed 2018-08-02 | $1.73M derived: sum of 3 quarters · filed 2019-02-28 | $2.14M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $587.00K 10-Q · filed 2018-05-09 | $987.00K derived: sum of 2 quarters · filed 2019-02-28 | $1.40M derived: sum of 3 quarters · filed 2019-02-28 | $2.04M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $813.00K derived: sum of 2 quarters · filed 2019-02-28 | $1.45M derived: sum of 3 quarters · filed 2019-02-28 | $2.13M 10-K · filed 2019-02-28 |
| 2016-09-30 | $413.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $1.05M derived: sum of 2 quarters · filed 2017-11-08 | $1.74M 10-Q · filed 2017-11-08 | $2.34M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $638.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $1.32M 10-Q · filed 2017-08-09 | $1.93M derived: sum of 3 quarters · filed 2018-02-28 | |
| 2016-03-31 | $684.00K 10-Q · filed 2017-05-10 | $1.29M derived: sum of 2 quarters · filed 2018-02-28 | ||
| 2015-12-31 | $606.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $2.65M 10-K · filed 2018-02-28 | ||
| 2015-09-30 | $2.04M 10-Q · filed 2016-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |